Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies

Human Gene Therapy

Volumn 11, Issue 10, 2000, Pages 1407-1415

  Pelegrin, Mireia ^a   Marin, Mariana ^a   Oates, Anna ^a   Noël, Danièle ^a   Saller, Robert ^b   Salmons, Brian ^b   Piechaczyk, Marc ^a  

^a CNRS   (France)

^b Bavarian Nordic GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE SULFATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ARTICLE; CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; GENETIC ENGINEERING; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NERVE DEGENERATION; NEWBORN; NONHUMAN; RETROVIRUS; RHEUMATOID ARTHRITIS; VIREMIA; VIRUS INFECTION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; BRAIN; CELL LINE; FRIEND MURINE LEUKEMIA VIRUS; HUMANS; IMMUNOTHERAPY; MICE; RETROVIRIDAE; THYROGLOBULIN; TIME FACTORS; VIREMIA;

EID: 0034234842     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050057486     Document Type: Article

References (31)

1. BAERT, F.J., D'HAENS, G.R., PEETERS, M., HIELE, M.I., SCHAIBLE, T.F., SHEALY, D., GEBOES, K., and RUTGEERTS, P.J. (1999). Tumor necrosis factor alpha antibody (inflixim ab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116, 22-28.
2. BASELGA, J., TRIPATHY, D., MENDELSOHN, J., BAUGHMAN, S., BENZ, C.C., DANTIS, L., SKLARIN, N.T., SEIDMAN, A.D., HUDIS, C.A., MOORE, J., ROSEN, P.P., TWADDELL, T., HENDERSON, I.C., and NORTON, L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744.
3. CHESEBRO, B., BRITT, W., EVANS, L., WEHRLY, K., NISHIO, J., and CLOYD, M. (1983). Characterization of monoclonal antibodies reactive with murine leukemia viruses: Use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology 127, 134-148.
4. COLE, K.S., ROWLES, J.L., JAGERSKI, B.A., MURPHEY, C.M., UNANGST, T., CLEMENTS, J.E., ROBINSON, J., WYAND, M.S., DESROSIERS, R.C., and MONTELARO, R.C. (1997). Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 71, 5069-5079.
5. DALGLEISH, A.G. (1995). The immune response to HIV: Potential for immunotherapy? Immunol. Today 16, 356-358.
6. DAUTZENBERG, H., SCHULDT, U., GRASNICK, G., KARLE, P., MULLER, P., LOHR, M., PELEGRIN, M., PIECHACZYK, M., ROMBS, K. V., GUNZBURG, W.H., SALMONS, B., and SALLER, R.M. (1999). Development of cellulose sulphate-based polyelectrolyte complex microcapsules for medical applications. Ann. N.Y. Acad. Sci. 875, 46-63.
7. D'HAENS, G., VAN DEVENTER, S., VAN HOGEZAND, R., CHALMERS, D., KOTHE, C., BAERT, F., BRAAKMAN, T., SCHAIBLE, T., GEBOES, K., and RUTGEERTS, P. (1999). Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116, 1029-1034.
8. DITTMER, U., BROOKS, D.M., and HASENKRUG, K.J. (1999). Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nature Med. 5, 189-193.
9. ELLIOTT, M.J., MAINI, R.M., FELDMANN, M., KALDEN, J.R., ANTONI, C., SMOLEN, J.S., LEEB, B., BREEDVELD, F.C., MACFARLANE, J.D., BIJL, H. and WOODY, J.N. (1994a). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110.
10. ELLIOTT, M.J., MAINI, R.N., FELDMANN, M., LONG-FOX, A., CHARLES, P., BIJL, H., and WOODY, J.N. (1994b). Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127.
11. FELDMAN, M., TAYLOR, P., PALEOLOG, E., BRENNAN, F.M., and MAINI, R.N. (1998). Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases. Transplant. Proc. 30, 4126-4127.
12. HARLOW, E., and LANE, D. (1988). Antibodies: A Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
13. HASENKRUG, K.J., and CHESEBRO, B. (1997). Immunity to retroviral infection: The Friend virus model. Proc. Natl. Acad. Sci. U.S.A. 94, 7811-7816.
14. KUUS-REICHEL, K., GRAUER, L.S.., KARAVODIN, L.M., KNOTT, C., KRUSEMEIER, M., and KAY, N.E. (1994). Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1, 365-372.
15. MAINI, R.N., ELLIOTT, M.J., BRENNAN, F.M., WILLIAMS, R.O., CHU, C.Q., PALEOLOG, E., CHARLES, P.J., TAYLOR, P.C., and FELDMANN, M. (1995). Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144, 195-223.
16. MALONEY, D.G., GRILLO, L.A., WHITE, C.A., BODKIN, D., SCHILDER, R.J., NEIDHART, J.A., JANAKIRAMAN, N., FOON, K.A., LILES, T.M., DALLAIRE, B.K., WEY, K., ROYSTON, I., DAVIS, T., and LEVY, R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195.
17. MCATEE, F.J., and PORTIS, J.L. (1985). Monoclonal antibodies specific for wild mouse neurotropic retrovirus: Detection of comparable levels of virus replication in mouse strains susceptible and resistant to paralytic disease. J. Virol. 56, 1018-1022.
18. MORELAND, L.W. (1999). Inhibitors of tumor necrosis factor for rheumatoid arthritis. J. Rheumatol. 26, (Suppl. 57), 7-15.
19. NOËL, D., PELEGRIN, M., MARIN, M., BIARD, P.M., OURLIN, J.C., MANI, J.C., and PIECHACZYK, M. (1997). In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum. Gene Ther. 8, 1219-1229.
20. PEGRAM, M.D., LIPTON, A., HAYES, D.F., WEBER, B.L., BASELGA, J.M., TRIPATHY, D., BALY, D., BAUGHMAN, S.A., TWADDELL, T., GLASPY, J.A., and SLAMON, D.J. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671.
21. PELEGRIN, M., MARIN, M., NOEL, D., DEL, R.M., SALLER, R., STANGE, J., MITZNER, S., GUNZBURG, W.H., and PIECHACZYK, M. (1998). Systemic long-term delivery of anti-bodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther. 5, 828-834.
22. PIECHACZYK, M., CHARDES, T., COT, M.C., PAU, B., and BASTIDE, J.M. (1985). Production and characterization of monoclonal antibodies against human thyroglobulin. Hybridoma 4, 361-367.
23. PINCUS, S.H., COLE, R., IRELAND, R., MCATEE, F., FUJISAWA, R., and PORTIS, J. (1995). Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J. Virol. 69, 7152-7158.
24. PORTIS, J.L., CZUB, S., GARON, C.F., and MCATEE, F.J. (1990). Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gagpol sequences from nondefective Friend murine leukemia virus. J. Virol. 64, 1648-1656.
25. PUEYO, M.E., DARQUY, S., CAPRON, F., and REACH, G. (1993). In vitro activation of human macrophages by alginate-polylysin e microcapsules. J. Biomater. Sci. Polym. Ed. 5, 197-203.
26. REGULIER, E., SCHNEIDER, B.L., DEGLON, N., BEUZARD, Y., and AEBISCHER, P. (1998). Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther. 5, 1014-1022.
27. ROSS, J.S., and FLETCHER, J.A. (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 3, 237-252.
28. SAVELKOUL, H.F., VAN OMMEN, R., VOSSEN, A.C., BREEDLAND, E.G., COFFMAN, R.L., and VAN OUDENAREN, A. (1994). Modulation of systemic cytokine levels by implantation of alginate encapsulated cells. J. Immunol. Methods 170, 185-196.
29. TAI, I.T., and SUN, A.M. (1993). Microencapsulation of recombinant cells: A new delivery system for gene therapy. FASEB J. 7, 1061-1069.
30. VANDENBOSSCHE, G.M., BRACKE, M.E., CUVELIER, C.A., BORTIER, H.E., MAREEL, M.M., and REMON, J.P. (1993). Host reaction against empty alginate-polylysine microcapsules. Influence of preparation procedure. J. Pharm. Pharmocol. 45, 115-120.
31. VAUGHAN, T.J., OSBOURN, J.K., and TEMPEST, P.R. (1998). Human antibodies by design. Nature Biotechnol. 16, 535-539.